Patient-derived organoids as individual patient models for chemoradiation response prediction in gastrointestinal malignancies.

Abstract

Chemoradiotherapy (CRT) is an important treatment modality for specific gastrointestinal (GI) cancers, as it has been shown to improve clinical outcomes. Recent developments in the neoadjuvant setting such as wait-and-see strategies for rectal as well as for esophageal cancers have even proven that CRT might be an effective organ-sparing treatment. However, due to molecular heterogeneity, only a subset of patients will show a complete response to CRT, which addresses the need for an individualized treatment approach. In recent years, the demand for more physiologically relevant predictive in vitro models has fostered the development of patient-derived tumor organoids. In this review, we describe the current treatment options for patients with GI cancers who are treated with (neo)adjuvant CRT. Furthermore, we provide an in-depth discussion of the organoid technology in the context of predicting CRT response for GI cancers as well as possible challenges for clinical implementation.

• Authors: Maxim Le Compte, Niels Komen, Ines Joye, Marc Peeters, Hans Prenen, Evelien Smits, Christophe Deben, Michiel de Maat
• Journal: Critical reviews in oncology/hematology (Crit Rev Oncol Hematol) Vol. 157 Pg. 103190 (Jan 2021) ISSN: 1879-0461 [Electronic] Netherlands
• PMID: 33310278 (Publication Type: Journal Article, Review)
• Copyright: Copyright © 2020 Elsevier B.V. All rights reserved.

Topics

• Chemoradiotherapy
• Humans
• Neoadjuvant Therapy
• Organoids
• Rectal Neoplasms
• Treatment Outcome